Last updated on June 3, 2012 at 17:03 EDT
Log In
and
Sign Up
with:
Log out
Home
Video
News
Images
Health
Education
Topics
Mobile
News - KCP
Statement By KCP Chairman Dr. Edward Jones in Response to FDA Advisory Committee on Benefits and Risks of Erythropoietin-Stimulating Agents in Treatment of Kidney Patients
2007-09-12 18:00:39
WASHINGTON, Sept. 12 /PRNewswire-USNewswire/ -- The following is a statement by KCP Chairman Dr.
More News (1 articles) »